Table 1. The frequency distribution of the lesion patterns in the different experimental groups shows a trend to a more favourable outcome (pattern C) in the combined treatment groups.
| Group | Pattern | ||
|---|---|---|---|
| A | B | C | |
| Gn3 T1 group | 33.33% | 8.33% | 58.33% |
| Gn3 T2 group | 41.67% | 16.67% | 41.67% |
| Gn3+Gn32 combi T1 group | 16.67% | 16.67% | 66.67% |
| Gn3+Gn32 combi T2 group | 0% | 9.09% | 90.91% |
| PBS group | 70.83% | 8.33% | 20.83% |
Pattern A: “Early-onset fatal hepatitis” characterized by severe, acute, coalescing to diffuse hepatitis and RVFV-antigen mainly in hepatocytes, as well as lymphocytic depletion; Pattern B: “Late-onset fatal polioencephalitis” characterized by mild to moderate, acute, focal to multifocal, necrotizing polioencephalitis and RVFV-antigen within neuroglial cells, as well as variable, subacute hepatitis and lymphocytic depletion; Pattern C: “Survivor with reactive lymphoid hyperplasia” characterized by mild to moderate, subacute to chronic, follicular hyperplasia in the spleen, as well as mild, subacute hepatitis or periportal infiltration and/or no obvious lesions.